CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia

This is a Phase Ia, open label, dose finding single center trial designed to evaluate the maximum tolerated dose, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of CD19 CAR T cells targeting the B cell surface antigen CD19 following administration of chemotherapy lymphodepletion regimen in adults (age 18 - 75) with relapsed/refractory acute lymphoblastic leukemia (ALL).

NCT Number	NCT07361029
Lead Sponsor	King Faisal Specialist Hospital & Research Center Collaborators: Miltenyi Biomedicine GmbH
Conditions	Relapsed Refractory Acute Lymphoblastic Leukemia
Enrollment	24 participants
Start Date	2025-07-29
Primary Completion	2027-07 (estimated)
Study Completion	2028-07 (estimated)
Updated on ClinicalTrials.gov	2026-01-22